MedTrace Logo

EGFR CART Cells for Patients With Metastatic Colorectal Cancer

NCT03152435 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-08-16

No results posted yet for this study

Summary

This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR CART) cells in metastatic patients with colorectal cancer.

Conditions

  • EGFR-positive Colorectal Cancer

Interventions

BIOLOGICAL

EGFR CART

EGFR CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%).

Sponsors & Collaborators

  • The Beijing Pregene Science and Technology Company, Ltd.

    collaborator INDUSTRY

  • Shenzhen Second People's Hospital

    lead OTHER

Principal Investigators

  • geng tian · Shenzhen Second People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-15
Primary Completion
2019-09-30
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03152435 on ClinicalTrials.gov